Epigral Limited Valuation
EPIGRAL · Chemicals · Current price ₹994
Is Epigral Limited undervalued?
We estimate the fair value of Epigral Limited at ₹1,704 per share, against a market price of ₹1,131. That puts the share price about +50.6% below our estimate, at medium confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 2 methods: Normalized earnings (mid-cycle EV/EBITDA) (₹1,584), Fair multiple (P/E) (₹2,319). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for Epigral Limited spans ₹1,534 to ₹1,875. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Valuation multiples
Epigral Limited trades at a P/E of 12.9x and a P/B of 1.9x, with a dividend yield of 0.5%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
How we got this fair value
Every number below is part of the same estimate for Epigral Limited. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹1,534 – ₹1,875
Why this method for this business
Normalized earnings and EV/EBITDA are appropriate for a cyclical specialty chemicals business, while relative PE provides a sector benchmark.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
Cyclical valued off mid-cycle earnings and a through-cycle EV/EBITDA (§6.6)
required inputs missing
- DCF is not suitable for a cyclical business with volatile cash flows
- Book value is not relevant for an asset-light, earnings-driven business
What was missing
- Lack of forward EBITDA estimates
- Limited analyst coverage
- No clear sector re-rating history
What drives it
23 inputs, grouped by how strong each claim is
- Revenue (TTM)
- 2,527.2 ₹ cr
- Net debt
- 572 ₹ cr
- Shares outstanding
- 4,00,00,000
- Sector-median P/E
- 36.87×
- Peers used
- 28
- EPS (TTM)
- 62.99 ₹/share
- Own-history median P/E
- 15.7×
computed
computed
computed
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- EBITDA margin (cycle median)
- 28%
- Through-cycle EV/EBITDA
- 9.76×
computed (≤5y median)
own-history (median of 5y)
- Anchor correction
- peer anchor 36.9x diverges 0.4x from 5yr own-history 15.7x (no size-comparable peer) — anchor blended 0.6 toward own-history → 24.2x
- Term: quality
- +5.4%
- Term: growth
- +40.0%
- Term: capital_allocation
- +8.6%
- Term: financial_strength
- +5.0%
- Term: history
- -10.5%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
peer-anchor mismatch — deep own-history used instead
quality 66/100 (high, stable returns) → premium
durable ~26% CAGR (ROCE 22% > hurdle) → premium
capital allocation: rising ROCE funded by strong FCF → premium
financial strength: low leverage (D/E 0.3) → mild premium
history: market paid -35% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Mid-cycle EBITDA
- 707.6 ₹ cr
- Enterprise value
- 6,908 ₹ cr
- Premium vs sector
- +52.3%
- Fair-multiple confidence
- 82%
- Fair P/E
- 36.81×
computed
computed
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Epigral Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 15 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyUnderstand the ratios
More on Epigral Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.